{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:13:49Z","timestamp":1792462429044,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","award":["WO2021062169A1"],"award-info":[{"award-number":["WO2021062169A1"]}],"id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01 EY017011"],"award-info":[{"award-number":["R01 EY017011"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01 EY015130"],"award-info":[{"award-number":["R01 EY015130"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["R01 EY14370"],"award-info":[{"award-number":["R01 EY14370"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["R01 EY017313"],"award-info":[{"award-number":["R01 EY017313"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["7-21-PDF-022"],"award-info":[{"award-number":["7-21-PDF-022"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["R01 E022230"],"award-info":[{"award-number":["R01 E022230"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["R01 EY1333516"],"award-info":[{"award-number":["R01 EY1333516"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001209","name":"Knights Templar Eye Foundation","doi-asserted-by":"publisher","award":["R01EY017011"],"award-info":[{"award-number":["R01EY017011"]}],"id":[{"id":"10.13039\/100001209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation United States of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013884","name":"Macula Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.xops.2024.100521","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:35:06Z","timestamp":1711499706000},"page":"100521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease"],"prefix":"10.1016","volume":"4","author":[{"given":"M. Elizabeth","family":"Hartnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ward","family":"Fickweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Adamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arup","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia J.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-8469","authenticated-orcid":false,"given":"Edward P.","family":"Feener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0335-5881","authenticated-orcid":false,"given":"George","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Kowluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-1951","authenticated-orcid":false,"given":"Ulrich F.O.","family":"Luhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2012-3465","authenticated-orcid":false,"given":"Lloyd Paul","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2024.100521_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xops.2024.100521_bib2","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","year":"2016"},{"key":"10.1016\/j.xops.2024.100521_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100521_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cyto.2007.09.001","article-title":"Angiopoietin modulation of vascular endothelial growth factor: effects on retinal endothelial cell permeability","volume":"40","author":"Peters","year":"2007","journal-title":"Cytokine"},{"key":"10.1016\/j.xops.2024.100521_bib5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100521_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2024.100521_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2024.100521_bib8","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.xops.2024.100521_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2337\/dc13-2251","article-title":"Diabetic retinopathy and other ocular findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"Aiello","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xops.2024.100521_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ophtha.2021.07.009","article-title":"Intravitreal pharmacotherapies for diabetic macular edema: a report by the American Academy of Ophthalmology","volume":"129","author":"Ehlers","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100521_bib11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/IAE.0000000000003730","article-title":"Defining \u201cstrong\u201d versus \u201cweak\u201d response to antivascular endothelial growth factor treatment for center-involved diabetic macular edema","volume":"43","author":"Sun","year":"2023","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100521_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11892-011-0204-0","article-title":"Microvascular modifications in diabetic retinopathy","volume":"11","author":"Durham","year":"2011","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.xops.2024.100521_bib13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/cells9081849","article-title":"Cross-talk between NADPH oxidase and mitochondria: role in ROS signaling and angiogenesis","volume":"9","author":"Fukai","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.xops.2024.100521_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.12.11.9","article-title":"Correlation of aqueous, vitreous, and serum protein levels in patients with retinal diseases","volume":"12","author":"Wilson","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100521_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9401628","article-title":"Serum vascular endothelial growth factor levels correlate with severity of retinopathy in diabetic patients: a systematic review and meta-analysis","volume":"2019","author":"Zhou","year":"2019","journal-title":"Dis Markers"},{"key":"10.1016\/j.xops.2024.100521_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40942-019-0179-6","article-title":"Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy","volume":"5","author":"Ahuja","year":"2019","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.xops.2024.100521_bib17","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc22-0165","article-title":"Elevated retinol binding protein 3 concentrations are associated with decreased vitreous inflammatory cytokines, VEGF, and progression of diabetic retinopathy","volume":"45","author":"Fickweiler","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xops.2024.100521_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00417-004-0950-7","article-title":"Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients","volume":"243","author":"Funatsu","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.61.2.26","article-title":"Correlation of aqueous, vitreous, and plasma cytokine levels in patients with proliferative diabetic retinopathy","volume":"61","author":"Wu","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ajo.2009.07.014","article-title":"Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus","volume":"148","author":"Hartnett","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/0974-9233.154388","article-title":"Diabetic retinopathy and systemic factors","volume":"22","author":"Frank","year":"2015","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0140-6736(75)92497-6","article-title":"Plasma-lipids and glucose\/insulin relationship in non-insulin-requiring diabetics with and without retinopathy","volume":"1","author":"Kissebah","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2024.100521_bib23","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.TR120000981","article-title":"Lipid metabolism dysregulation in diabetic retinopathy","volume":"62","author":"Busik","year":"2021","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.xops.2024.100521_bib24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xops.2024.100521_bib25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/eye.2011.62","article-title":"Medical management of diabetic retinopathy: fenofibrate and ACCORD eye studies","volume":"25","author":"Wright","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2024.100521_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1011499","article-title":"Update of the ACCORD eye study","volume":"364","author":"Chew","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xops.2024.100521_bib27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11892-016-0786-7","article-title":"Fenofibrate and diabetic retinopathy","volume":"16","author":"Knickelbein","year":"2016","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.xops.2024.100521_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaophthalmol.2022.0633","article-title":"Association of fenofibrate use and the risk of progression to vision-threatening diabetic retinopathy","volume":"140","author":"Meer","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib29","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1073\/pnas.1307211110","article-title":"Pathogenic role of diabetes-induced PPAR-\u03b1 down-regulation in microvascular dysfunction","volume":"110","author":"Hu","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2024.100521_bib30","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ajpath.2014.06.021","article-title":"Peroxisome proliferator-activated receptor \u03b1 protects capillary pericytes in the retina","volume":"184","author":"Ding","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.xops.2024.100521_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208399","article-title":"Neuroprotective effects of PPAR\u03b1 in retinopathy of type 1 diabetes","volume":"14","author":"Pearsall","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2024.100521_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.preteyeres.2015.05.001","article-title":"Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy","volume":"48","author":"Kowluru","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2024.100521_bib33","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.bbadis.2015.08.001","article-title":"Oxidative stress, mitochondrial damage and diabetic retinopathy","volume":"1852","author":"Kowluru","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xops.2024.100521_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nm1534","article-title":"Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation","volume":"13","author":"Gao","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.xops.2024.100521_bib35","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.2337\/db15-0317","article-title":"Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema","volume":"64","author":"Kita","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2024.100521_bib36","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.2337\/db10-1260","article-title":"Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats","volume":"60","author":"Clermont","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2024.100521_bib37","first-page":"4863","article-title":"Novel oral plasma kallikrein inhibitor KV998076 is protective against intravitreal VEGF and TNF\u03b1 induced retinal edema and neuroretinal dysfunction","volume":"61","author":"Murugesan","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib38","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.oret.2019.07.006","article-title":"One-time intravitreal injection of KVD001, a plasma kallikrein inhibitor, in patients with central-involved diabetic macular edema and reduced vision: an open-label phase 1B study","volume":"3","author":"Sun","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100521_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/tvst.10.14.28","article-title":"Phase 1 dose-escalation study of plasma kallikrein inhibitor THR-149 for the treatment of diabetic macular edema","volume":"10","author":"Dugel","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100521_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/dom.12172","article-title":"Targeting inflammation in the treatment of type 2 diabetes","volume":"15 Suppl 3","author":"Donath","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.xops.2024.100521_bib41","first-page":"307","article-title":"Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy","volume":"61","author":"Mantripragada","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib42","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.oret.2018.06.005","article-title":"Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2024.100521_bib43","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100521_bib44","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1167\/iovs.10-6386","article-title":"A\u00a0potential role for angiopoietin 2 in the regulation of the blood\u2013retinal barrier in diabetic retinopathy","volume":"52","author":"Rangasamy","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.xops.2024.100521_bib46","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","article-title":"Diabetic macular edema: pathophysiology and novel therapeutic targets","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100521_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00281-008-0111-x","article-title":"Immunological mechanisms in the pathogenesis of diabetic retinopathy","volume":"30","author":"Adamis","year":"2008","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.xops.2024.100521_bib48","article-title":"Intravitreal steroids for macular edema in diabetes","volume":"11","author":"Rittiphairoj","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2024.100521_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108508","article-title":"Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy","volume":"9","author":"Rangasamy","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2024.100521_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","article-title":"Association of vitreous inflammatory factors with diabetic macular edema","volume":"116","author":"Funatsu","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2024.100521_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00417-020-04884-5","article-title":"A\u00a0potential novel therapeutic target in diabetic retinopathy: a chemokine receptor (CCR2\/CCR5) inhibitor reduces retinal vascular leakage in an animal model","volume":"259","author":"Monickaraj","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib52","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1167\/iovs.17-22731","article-title":"A\u00a0CCR2\/5 inhibitor, PF-04634817, is inferior to monthly ranibizumab in the treatment of diabetic macular edema","volume":"59","author":"Gale","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib53","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1096\/fj.01-0707fje","article-title":"Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression","volume":"16","author":"Joussen","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.xops.2024.100521_bib54","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2337\/dc09-2372","article-title":"Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study","volume":"33","author":"Sfikakis","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xops.2024.100521_bib55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12348-014-0026-8","article-title":"Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders","volume":"4","author":"Pascual-Camps","year":"2014","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.xops.2024.100521_bib56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/IAE.0b013e3181eac7a6","article-title":"Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.xops.2024.100521_bib57","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/aos.14891","article-title":"Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta-analysis","volume":"100","author":"Minaker","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6928524","article-title":"Aqueous humor mediator and cytokine aberrations in diabetic retinopathy and diabetic macular edema: a systematic review and meta-analysis","volume":"2019","author":"Wu","year":"2019","journal-title":"Dis Markers"},{"key":"10.1016\/j.xops.2024.100521_bib59","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0002-9394(14)74052-8","article-title":"Cytokines in the vitreous of patients with proliferative diabetic retinopathy","volume":"114","author":"Abu el Asrar","year":"1992","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1056-8727(01)00155-6","article-title":"Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy","volume":"15","author":"Yuuki","year":"2001","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.xops.2024.100521_bib61","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1016\/S0042-6989(99)00117-0","article-title":"L-arginine transport in retinas from streptozotocin diabetic rats: correlation with the level of IL-1 beta and NO synthase activity","volume":"39","author":"Carmo","year":"1999","journal-title":"Vis Res"},{"key":"10.1016\/j.xops.2024.100521_bib62","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/434010","article-title":"Cytokine levels in the serum of healthy subjects","volume":"2013","author":"Kleiner","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.xops.2024.100521_bib63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/tvst.10.12.8","article-title":"Circulating biomarkers of inflammation and endothelial activation in diabetic retinopathy","volume":"10","author":"Storti","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100521_bib64","first-page":"1062","article-title":"Optimized IL-6 blockade for the treatment of diabetic macular edema","volume":"55","author":"Schmidt","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib65","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1210\/er.2019-00002","article-title":"Inflammation in the pathophysiology and therapy of cardiometabolic disease","volume":"40","author":"Donath","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.xops.2024.100521_bib66","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1167\/iovs.17-22816","article-title":"Enhanced expression of NLRP3 inflammasome-related inflammation in diabetic retinopathy","volume":"59","author":"Chen","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib67","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.2337\/db06-1694","article-title":"Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes","volume":"56","author":"Navaratna","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2024.100521_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144406","article-title":"Relationship between C-reactive protein level and diabetic retinopathy: a systematic review and meta-analysis","volume":"10","author":"Song","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2024.100521_bib69","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11892-013-0382-z","article-title":"Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema","volume":"13","author":"Owen","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.xops.2024.100521_bib70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2337\/diacare.23.2.234","article-title":"Serum markers of oxidative stress and severity of diabetic retinopathy","volume":"23","author":"Hartnett","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xops.2024.100521_bib71","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1167\/iovs.10-5881","article-title":"AGEs and diabetic retinopathy","volume":"51","author":"Stitt","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5301\/EJO.2010.4447","article-title":"Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy","volume":"21","author":"Ghanem","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cbi.2011.01.007","article-title":"Advanced lipoxidation end-products","volume":"192","author":"Pamplona","year":"2011","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.xops.2024.100521_bib74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/02713688408997203","article-title":"Lipid peroxidation and retinal degeneration","volume":"3","author":"Anderson","year":"1984","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.xops.2024.100521_bib75","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00125-008-1071-3","article-title":"Evaluation of N (epsilon)-(3-formyl-3,4-dehydropiperidino)lysine as a novel biomarker for the severity of diabetic retinopathy","volume":"51","author":"Zhang","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.xops.2024.100521_bib76","article-title":"The role of lipoxidation in the pathogenesis of diabetic retinopathy","volume":"11","author":"Augustine","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.xops.2024.100521_bib77","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.visres.2017.06.016","article-title":"Hematopoietic stem\/progenitor involvement in retinal microvascular repair during diabetes: implications for bone marrow rejuvenation","volume":"139","author":"Bhatwadekar","year":"2017","journal-title":"Vis Res"},{"key":"10.1016\/j.xops.2024.100521_bib78","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/eye.2016.94","article-title":"Revisiting the role of erythropoietin for treatment of ocular disorders","volume":"30","author":"Shirley Ding","year":"2016","journal-title":"Eye"},{"key":"10.1016\/j.xops.2024.100521_bib79","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.ki.5001546","article-title":"Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise","volume":"70","author":"Brines","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.xops.2024.100521_bib80","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2119\/molmed.2011.00414","article-title":"The receptor that tames the innate immune response","volume":"18","author":"Brines","year":"2012","journal-title":"Mol Med"},{"key":"10.1016\/j.xops.2024.100521_bib81","first-page":"526","article-title":"Erythropoietin deficiency decreases vascular stability in mice","volume":"118","author":"Chen","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xops.2024.100521_bib82","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/iovs.61.10.23","article-title":"Signaling through the erythropoietin receptor affects angiogenesis in retinovascular disease","volume":"61","author":"Bretz","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib83","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ajpath.2019.11.009","article-title":"Erythropoietin receptor signaling supports retinal function after vascular injury","volume":"190","author":"Bretz","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.xops.2024.100521_bib84","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1073\/pnas.98.3.986","article-title":"Mouse model of congenital polycythemia: homologous replacement of murine gene by mutant human erythropoietin receptor gene","volume":"98","author":"Divoky","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2024.100521_bib85","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/s41598-018-20520-z","article-title":"Erythropoietin signaling increases choroidal macrophages and cytokine expression, and exacerbates choroidal neovascularization","volume":"8","author":"Bretz","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2024.100521_bib86","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archophthalmol.2009.355","article-title":"Association between erythropoietin gene polymorphisms and diabetic retinopathy","volume":"128","author":"Abhary","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib87","first-page":"2225","article-title":"A\u00a0phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema","volume":"9","author":"Lois","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.xops.2024.100521_bib88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.visres.2017.06.014","article-title":"Neurodegeneration in diabetic retinopathy: potential for novel therapies","volume":"139","author":"Barber","year":"2017","journal-title":"Vis Res"},{"key":"10.1016\/j.xops.2024.100521_bib89","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2337\/dc10-1675","article-title":"Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study","volume":"34","author":"Sun","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xops.2024.100521_bib90","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI2425","article-title":"Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin","volume":"102","author":"Barber","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.xops.2024.100521_bib91","doi-asserted-by":"crossref","first-page":"E2655","DOI":"10.1073\/pnas.1522014113","article-title":"Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus","volume":"113","author":"Sohn","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2024.100521_bib92","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/nu14040792","article-title":"Understanding neurodegeneration from a clinical and therapeutic perspective in early diabetic retinopathy","volume":"14","author":"Fragiotta","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.xops.2024.100521_bib93","doi-asserted-by":"crossref","first-page":"16586","DOI":"10.1073\/pnas.1314575110","article-title":"Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina","volume":"110","author":"Du","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2024.100521_bib94","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.cmet.2013.09.003","article-title":"Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1","volume":"18","author":"Cerani","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.xops.2024.100521_bib95","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2337\/db20-1220","article-title":"Vascular expression of permeability-resistant occludin mutant preserves visual function in diabetes","volume":"70","author":"Goncalves","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2024.100521_bib96","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.survophthal.2021.08.011","article-title":"Clinical electroretinography in diabetic retinopathy: a review","volume":"67","author":"McAnany","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib97","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2337\/db16-1453","article-title":"Functional and structural findings of neurodegeneration in early stages of diabetic retinopathy: cross-sectional analyses of baseline data of the EUROCONDOR project","volume":"66","author":"Santos","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2024.100521_bib98","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/APO.0000000000000510","article-title":"Diabetic retinopathy: role of neurodegeneration and therapeutic perspectives","volume":"11","author":"Sim\u00f3","year":"2022","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.xops.2024.100521_bib99","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1167\/iovs.18-26487","article-title":"Topical treatment with brimonidine and somatostatin causes retinal vascular dilation in patients with early diabetic retinopathy from the EUROCONDOR","volume":"60","author":"Grauslund","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000444396","article-title":"Correlation between retinal vessel calibre and neurodegeneration in patients with type 2 diabetes mellitus in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)","volume":"56","author":"Frydkjaer-Olsen","year":"2016","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.xops.2024.100521_bib101","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2337\/db18-0682","article-title":"Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy: results of the EUROCONDOR clinical trial","volume":"68","author":"Sim\u00f3","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2024.100521_bib102","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2024.100521_bib103","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/dbi18-0016","article-title":"Mitochondrial stability in diabetic retinopathy: lessons learned from epigenetics","volume":"68","author":"Kowluru","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.xops.2024.100521_bib104","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1167\/iovs.03-0353","article-title":"Diabetes-induced mitochondrial dysfunction in the retina","volume":"44","author":"Kowluru","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/bjo.2007.132308","article-title":"Mitochondria- and caspase-dependent cell death pathway involved in neuronal degeneration in diabetic retinopathy","volume":"92","author":"Oshitari","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.190","article-title":"TXNIP regulates mitophagy in retinal M\u00fcller cells under high-glucose conditions: implications for diabetic retinopathy","volume":"8","author":"Devi","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.xops.2024.100521_bib107","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020104705","article-title":"Molecular mechanisms and physiological functions of mitophagy","volume":"40","author":"Onishi","year":"2021","journal-title":"EMBO J"},{"key":"10.1016\/j.xops.2024.100521_bib108","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.3390\/ijms22083903","article-title":"Mitophagy in human diseases","volume":"22","author":"Doblado","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xops.2024.100521_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2020.111207","article-title":"Mitophagy and DNA damage signaling in human aging","volume":"186","author":"Babbar","year":"2020","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.xops.2024.100521_bib110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12035-023-03534-1","article-title":"Impaired removal of the damaged mitochondria in the metabolic memory phenomenon associated with continued progression of diabetic retinopathy","volume":"61","author":"Kowluru","year":"2024","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.xops.2024.100521_bib111","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1167\/iovs.16-19073","article-title":"Peripheral blood mitochondrial DNA damage as a potential noninvasive biomarker of diabetic retinopathy","volume":"57","author":"Mishra","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2024.100521_bib112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1167\/tvst.8.6.43","article-title":"Epigenetic modifications in peripheral blood as potential noninvasive biomarker of diabetic retinopathy","volume":"8","author":"Duraisamy","year":"2019","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2024.100521_bib113","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56614-5","article-title":"Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment","volume":"9","author":"Castellazzi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2024.100521_bib114","article-title":"Leber's hereditary optic neuropathy-gene therapy: from benchtop to bedside","volume":"2011","author":"Koilkonda","year":"2011","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.xops.2024.100521_bib115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40123-020-00278-2","article-title":"The gut-eye axis: lessons learned from murine models","volume":"9","author":"Floyd","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.xops.2024.100521_bib116","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/978-3-319-75402-4_53","article-title":"The role of microbiota in retinal disease","volume":"1074","author":"Rowan","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.xops.2024.100521_bib117","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ Res"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914524000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:37:54Z","timestamp":1778924274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914524000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":117,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666914524000575"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2024.100521","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale of Basic and Cellular Mechanisms Considered in Updating the Staging System for Diabetic Retinal Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2024.100521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100521"}}